Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 8/20 | 1.00 |
| ▸ | SI | P14410 | 7/20 | 1.00 |
| ▸ | AMY2A | P04746 | 8/20 | 0.68 |
| ▸ | GAA | P10253 | 4/20 | 0.67 |
| ▸ | AMY1A | P0DUB6 | 3/20 | 0.67 |
| ▸ | CNR1 | P21554 | 1/20 | 0.67 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.67 |
| ▸ | PDE4A | P27815 | 1/20 | 0.67 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.67 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | GLA | P06280 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14408601 | 1.00 | MGAM (1.00) | MGAMSIAMY2AGAAAMY1A | |
| SCHEMBL14408602 | 1.00 | MGAM (1.00) | MGAMSIAMY2AGAAAMY1A | |
| SCHEMBL30937785 | 1.00 | MGAM (1.00) | MGAMSIAMY2AGAAAMY1A | |
| SCHEMBL14408731 | 1.00 | MGAM (1.00) | MGAMSIAMY2AGAAAMY1A | |
| SCHEMBL14408476 | 1.00 | MGAM (1.00) | MGAMSIAMY2AGAAAMY1A | |
| SCHEMBL5158956 | 1.00 | MGAM (1.00) | MGAMSIAMY2AGAAAMY1A | |
| SCHEMBL14408605 | 1.00 | MGAM (1.00) | MGAMSIAMY2AGAAAMY1A | |
| SCHEMBL14408698 | 1.00 | MGAM (1.00) | MGAMSIAMY2AGAAAMY1A | |
| SCHEMBL14408606 | 1.00 | MGAM (1.00) | MGAMSIAMY2AGAAAMY1A | |
| SCHEMBL14416167 | 0.89 | AMY2A (0.87) | MGAMSIAMY2AGAAAMY1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144747-A1 | SHIKIMATE ANALOGUES AND METHODS OF USE | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA | 2022-05-12 | — | — | US | claimed |
| US-12599562-B2 | Nanocrystal microparticles of poorly soluble drugs and methods of production and use thereof | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2026-04-14 | — | — | US | disclosed |
| EP-3880688-B1 | OLIGOSACCHARIDE PREPARATIONS AND COMPOSITIONS | DSM IP ASSETS BV (NL) | 2025-09-17 | — | — | EP | disclosed |
| EP-4613755-A1 | OLIGOSACCHARIDE PREPARATIONS AND COMPOSITIONS | DSM IP Assets B.V. (NL) | 2025-09-10 | — | — | EP | disclosed |
| US-12383570-B2 | Methods of selectively modulating gastrointestinal microbial growth | DSM IP ASSETS B.V. (NL) | 2025-08-12 | — | — | US | disclosed |
| US-12377113-B2 | Glycan therapeutic compositions and related methods thereof | DSM NUTRITIONAL PRODUCTS, LLC (US) | 2025-08-05 | — | — | US | disclosed |
| US-20250212913-A1 | METHODS OF MODULATING GASTROINTESTINAL METABOLITES | DSM IP ASSETS BV (NL) | 2025-07-03 | — | — | US | disclosed |
| US-20250185694-A1 | METHODS OF MODULATING GASTROINTESTINAL METABOLITES | DSM IP ASSETS BV (NL) | 2025-06-12 | — | — | US | disclosed |
| US-20250185695-A1 | METHODS OF MODULATING GASTROINTESTINAL METABOLITES | DSM IP ASSETS BV (NL) | 2025-06-12 | — | — | US | disclosed |
| US-20250185692-A1 | METHODS OF MODULATING GASTROINTESTINAL METABOLITES | DSM IP ASSETS BV (NL) | 2025-06-12 | — | — | US | disclosed |
| CN-107427528-B | Glycan therapeutics and methods related thereto | 卡莱多生物科技有限公司 | 2022-09-23 | — | — | CN | disclosed |
| EP-4045520-A1 | METHODS FOR THE IMPROVED FORMATION OF ACARBOSE | Bayer Aktiengesellschaft (DE) | 2022-08-24 | — | — | EP | disclosed |
| US-20220233577-A1 | GLYCAN PREPARATIONS AND METHODS OF USE FOR HYPERAMMONEMIA | KALEIDO BIOSCIENCES, INC. | 2022-07-28 | — | — | US | disclosed |
| US-11369592-B2 | Treatment of human coronavirus infections using alpha-glucosidase glycoprotein processing inhibitors | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| CN-114555811-A | Method for improving acarbose formation | 拜耳公司 | 2022-05-27 | — | — | CN | disclosed |
| US-20220144747-A1 | SHIKIMATE ANALOGUES AND METHODS OF USE | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA | 2022-05-12 | — | — | US | disclosed |
| US-20220125074-A1 | METHODS OF MODULATING GASTROINTESTINAL METABOLITES | DSM IP ASSETS B.V. (NL) | 2022-04-28 | — | — | US | disclosed |
| US-7271158-B2 | Treatment of rumen acidosis with α-amylase inhibitors | PFIZER INC. (US) | 2007-09-18 | — | — | US | disclosed |
| EP-1745790-A2 | Treatment of rumen acidosis with alpha-amylase inhibitors | Pfizer Limited (GB) | 2007-01-24 | — | — | EP | disclosed |
| US-20050233983-A1 | Treatment of rumen acidosis with alpha-amylase inhibitors | BANKS BERNARD J | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11369592-B2 | Treatment of human coronavirus infections using alpha-glucosidase glycoprotein processing inhibitors | ACE2, ACE, GAA | MGAM 12/4885SI 27/4885AMY2A 94/4885 |
| US-12599562-B2 | Nanocrystal microparticles of poorly soluble drugs and methods of production and use thereof | CDK4, CDK5, CDK6 | MGAM 3058/4885SI 1182/4885AMY2A 4239/4885 |
| US-20050233983-A1 | Treatment of rumen acidosis with alpha-amylase inhibitors | SI, GANAB, AMY1A | MGAM 7/4885SI 1/4885AMY2A 13/4885 |
| US-20220144747-A1 | SHIKIMATE ANALOGUES AND METHODS OF USE | GRIK5, GRIK1, GRIK3 | MGAM 2059/4885SI 67/4885AMY2A 2355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.